Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in Items 6, 8 and 9 reflect 123,755,000 shares of Class B common stock held directly by ULSE Inc., which are convertible at any time at the option of the holder into Class A common stock on a one-for-one basis. The percent of Class A common stock reported in Item 11 is based on 77,257,235 shares of Class A common stock outstanding as of December 19, 2025, based on information in the Issuer's prospectus supplement on Form 424B7 filed with the Securities and Exchange Commission (the "SEC") on December 5, 2025 and information from the Issuer, plus 123,755,000 shares of Class A common stock issuable upon the conversion of Class B common stock.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in Items 6, 8 and 9 reflect 123,755,000 shares of Class B common stock held directly by ULSE Inc., which are convertible at any time at the option of the holder into Class A common stock on a one-for-one basis. The percent of Class A common stock reported in Item 11 is based on 77,257,235 shares of Class A common stock outstanding as of December 19, 2025, based on information in the Issuer's prospectus supplement on Form 424B7 filed with the Securities and Exchange Commission (the "SEC") on December 5, 2025 and information from the Issuer, plus 123,755,000 shares of Class A common stock issuable upon the conversion of Class B common stock.


SCHEDULE 13G



 
ULSE Inc.
 
Signature:/s/ Doris Concepcion
Name/Title:Doris Concepcion, Interim Chief Financial Officer
Date:02/10/2026
 
Underwriters Laboratories Inc.
 
Signature:/s/ D. Michael Murray
Name/Title:D. Michael Murray, Vice President, Corporate Affairs
Date:02/10/2026